Power Law company profile

Alder Biopharmaceuticals

Biotech & Life Sciences · Bothell, United States · Founded 2004 · IPO 2014 Unicorn

← All companies

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation

$1.95B

Market cap · 2026

Revenue

$1.0M

Latest reported FY

Investors

7 investors on Alder Biopharmaceuticals's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series A 1 investor entered at this stage

Sevin Rosen Funds

Series B+ 6 investors entered at this stage

Patent intelligence

$129M patent portfolio · 25 active families

Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with topic prominence vs same-sector peers.

Estimated portfolio value

$129M

6.6% of market cap · 2.5× smaller than top peer Genmab ($328M)

25 active patent families

Where Alder Biopharmaceuticals innovates Antiendomysial antibodiesAnti antibodyMolecular biologyAntagonistDisease

Tech-focus vs peers

Where Alder Biopharmaceuticals concentrates inside the peer cluster

Axes are the most-shared Patsnap topics across Alder Biopharmaceuticals and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).

Compare against

Top-topic prominence (rank inverted, 0–100)

Source: Dealroom Patent Intelligence · Patsnap top-10 topics per company

This is teaser data. The full per-sub-category breakdown, individual patent records, and quality-score history are on the Dealroom platform — request a demo to access.

See Alder Biopharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Open in Dealroom Book a demo